Navigation Links
Depomed Announces District Court Order in ANDA Litigation
Date:7/17/2014

NEWARK, Calif., July 17, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that on July 17, 2014, Judge Joel A. Pisano of the United States District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise® (gabapentin) prior to the Court's issuance of an opinion in the matter.  The order indicates the Court expects to issue an opinion in short order.  The patents asserted in the lawsuits expire between September 2016 and February 2024 and include U.S. Patent Nos. 6,635,280; 6,488,962; 7,438,927; 7,731,989; 8,192,756; 8,252,332; and 8,333,992.

On May 20, 2014, a bench trial was completed before Judge Pisano in the patent litigation between Depomed and defendants Actavis Elizabeth LLC and Actavis Inc. related to an Abbreviated New Drug Application filed by Actavis seeking to market generic versions of 300mg and 600mg dosage strengths of Gralise  prior to the expiration of the patents asserted in the litigation.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology.   Additional information about Depomed may be found at www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.  The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the outcome of the Actavis litigation and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2014 and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.  The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

INVESTOR CONTACT:
August J. Moretti
Depomed, Inc.
510-744-8000
amoretti@depomed.com

MEDIA CONTACT:
Carolyn Hawley
Canale Communications for Depomed
619-849-5375
carolyn@canalecomm.com


'/>"/>
SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer
2. Depomed To Present At Piper Jaffray 2013 Healthcare Conference
3. Depomed Reports Third Quarter 2013 Financial Results
4. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
5. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
6. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
7. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
8. Depomed Reports Second Quarter 2013 Financial Results
9. Depomed To Report Second Quarter Fiscal Year 2013 Financial Results On Wednesday, August 7, 2013
10. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
11. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
(Date:5/4/2017)... , May 4, 2017  A recent study ... Ultraviolet-C light as a means of ... ability to reduce bioburden on anesthesia workstations. In ... on high-touch, complex medical equipment surfaces contaminated with ... "This study further validates the body ...
Breaking Medicine Technology:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new ... building collagen and elastin in their face, neck, and body through a virtually ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... patients on peri-implantitis in Las Vegas, NV, and the importance of ... gum disease consultation and leading care for peri-implantitis, with or without a referral. ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... availability of video chat as a standard feature on its secure clinical communication ... text to voice to video depending on the type and urgency of a ...
(Date:5/23/2017)... Boston, MA (PRWEB) , ... May 23, 2017 , ... ... workshop on Tuesday, May 23, 2017 in San Francisco. Titled Connected Health and ... Premier Connected Home Event hosted by Parks Associates, a market research and consulting ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients looking ... Systemâ„¢ Orthodontics, with or without a referral, from the multi-specialty Dr. Smile practice. ... who is skilled in providing patients with the custom, convenient and long-lasting orthodontic ...
Breaking Medicine News(10 mins):